North America Liquid Biopsy Market (2025-2030)
The North America Liquid Biopsy Market was valued at $121.6 Million in 2025 and projected to reach to $208.2 Million by 2030, representing a compound annual growth rate of 11.4%. North America's liquid biopsy market is positioned for sustained growth through 2030, driven by increasing cancer incidence, aging populations, and widespread adoption of precision oncology.
North America Liquid Biopsy Market Trends and Insights
- Latin America's adoption of liquid biopsy technologies is accelerating due to rising cancer incidence, increasing healthcare investments, and growing awareness of non-invasive diagnostic solutions.
- The region's market expansion reflects Latin America's shift toward precision medicine and early disease detection capabilities. Driving Latin America's 11.4% compound annual growth rate are improving healthcare infrastructure, regulatory support for advanced diagnostics, and partnerships between regional healthcare providers and global diagnostic companies.
- Latin America's emerging middle class and enhanced reimbursement policies are making liquid biopsy tests more accessible across the region.
- By 2030, Latin America is expected to become a significant contributor to the global liquid biopsy market, supported by continued innovation and clinical validation of blood-based biomarker testing..
Key Market Statistics
- CAGR (2025-2030) 11.4% CAGR
- Market Size, 2025 ~USD 121.6 Million
- Forecast, 2030 ~USD 208.2 Million
- Geography North America
North America Liquid Biopsy Market Overview
Market Leadership :
North America dominates the global liquid biopsy market, with the US alone accounting for $1,660.1 million in 2025, representing over 60% of the regional market value and driving innovation in diagnostic technologies.
Robust Growth Trajectory :
The North American liquid biopsy market is expanding at a 11.4% CAGR, driven by advanced healthcare infrastructure, high cancer prevalence, and significant R&D investments from leading diagnostic companies.
Canada's Contribution :
Canada represents a significant secondary market within North America with $281.7 million in 2025, supported by universal healthcare coverage and increasing adoption of precision medicine diagnostics.
Technology Adoption :
North America leads in liquid biopsy adoption due to favorable reimbursement policies, FDA approvals, and strong clinical evidence supporting non-invasive cancer screening and monitoring applications.
North America Liquid Biopsy Market Dynamics
- The region's advanced healthcare infrastructure, robust regulatory framework, and significant healthcare spending create an ideal environment for market expansion.
- Major diagnostic companies continue to invest heavily in R&D, launching innovative liquid biopsy solutions for early cancer detection and treatment monitoring. The US market will remain the primary growth engine, while Canada contributes steady expansion through public healthcare initiatives and clinical integration.
- Reimbursement improvements, expanding clinical applications beyond oncology, and growing patient awareness of non-invasive diagnostic options will further accelerate market penetration across North America through 2030..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Danaher Corporation
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- Latin America's liquid biopsy market is valued at $121.6 million in 2025 and will reach $208.2 million by 2030, representing a 71.2% increase over five years.
- Latin America is growing at an 11.4% CAGR, driven by rising cancer prevalence, improved healthcare access, and adoption of precision medicine across the region.
- Latin America's market expansion is supported by regulatory approvals, reimbursement improvements, and strategic partnerships with international diagnostic firms.
- Latin America's emerging economies and growing middle class are creating new opportunities for liquid biopsy adoption in oncology, cardiovascular, and prenatal screening applications.
Liquid Biopsy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CIRCULATING TUMOR DNA (Circulating Biomarker Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 11.8% from 2025 to 2030 |
| Largest Segment | BLOOD (Sample Type) |
| Market Size Base Year (Billions) | ~USD 4.04 (2025) |
| Revenue Forecast (Billions) | ~USD 7.05 (2030) |
| Segments Covered | Product & Service, Circulating Biomarker Type, Technology, Application, Type, Clinical Application, Sample Type, End User |
North America Liquid Biopsy Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product & Service
- Assay Kits
- Instruments
- Services
By Circulating Biomarker Type
- Cell-Free Dna
- Circulating Tumor Cells
- Circulating Tumor Dna
- Extracellular Vesicles
- Other Circulating Biomarkers
By Technology
- Multi-Gene Parallel Analysis Using Ngs
- Single-Gene Analysis Using Pcr Microarrays
By Application
- Cancer Applications
- Non-Cancer Applications
By Type
- Breast Cancer
- Colorectal Cancer
- Infectious Disease Testing
- Lung Cancer
- Melanoma
- Non-Invasive Prenatal Testing
- Organ Transplantation
- Other Cancers
- Prostate Cancer
By Clinical Application
- Early Cancer Screening
- Recurrence Monitoring
- Therapy Selection
- Treatment Monitoring
By Sample Type
- Blood
- Other Sample Types
By End User
- Academic & Research Centers
- Hospitals & Physician Laboratories
- Hospitals & Physicians Laboratories
- Other End Users
- Reference Laboratories
Target Audience
- Diagnostic Company Executives : Need market sizing and growth forecasts to guide product development priorities, M&A strategies, and capital allocation decisions within the high-value North American liquid biopsy segment.
- Healthcare Investment Firms : Require detailed market valuations and regional growth projections to evaluate investment opportunities in North American diagnostic companies and assess portfolio company performance.
- Hospital & Laboratory Administrators : Seek market intelligence on liquid biopsy adoption trends and competitive offerings to inform procurement decisions, technology integration planning, and service expansion strategies.
- Pharmaceutical & Biotech Companies : Need market data to understand companion diagnostic opportunities, patient stratification potential, and commercial viability of liquid biopsy integration into oncology treatment protocols.
- Healthcare Consultants & Analysts : Require comprehensive North American market data to support client advisory work, competitive analysis, and strategic planning recommendations across the diagnostic and precision medicine sectors.
Key Companies in the North America Liquid Biopsy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Vaccines (pediatric, hexavalent, travel and epidemic),Immunology & Inflammation,Rare Diseases & Neurology, |
| CONMED CORPORATION | United States | Public Company | Orthopedic sports medicine and power tools (BioBrace, Y-Knot, Hall, related disposables),General surgery and minimally invasive platforms (AirSeal, Buffalo Filter, endomechanical, electrosurgery),Endoscopic technologies and patient monitoring (GI therapeutics, ECG/EEG, defibrillation pads), |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, markers, localization, treatment),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa ProVu, CoolSeal), |
| UNITED IMAGING HEALTHCARE CO., LTD. | China | Public Company | Magnetic Resonance Imaging,Computed Tomography,Molecular Imaging (PET/CT, SPECT), |
| NATERA, INC. | United States | Public Company | Oncology MRD and CGP (Signatera, Latitude, Altera, Empower oncology use),Women’s health (Panorama, Horizon, Fetal Focus, Vistara, Anora),Transplant and nephrology (Prospera, Renasight), |
| GUARDANT HEALTH | United States | Public Company | Guardant360 liquid portfolio (CDx and Guardant360 Liquid),Guardant Reveal and minimal residual disease testing,Guardant360 Tissue and tissue-based profiling, |
| MYRIAD GENETICS, INC. | United States | Public Company | Hereditary and Companion Diagnostics (MyRisk, BRACAnalysis CDx, MyChoice CDx),Oncology Prognostics and Tumor Profiling (Prolaris, EndoPredict, Precise Tumor),Women’s Health and Prenatal (Prequel, Foresight, SneakPeek, FirstGene), |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Arrays and genotyping products, |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual and reproductive health assays, |
| EXACT SCIENCES CORPORATION | United States | Private Company | Cologuard and Cologuard Plus,Oncotype DX breast and colon tests,Hereditary and risk assessment tests (Riskguard, Cancerguard, Genetic Testing), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| GRAIL, INC. | United States | Public Company | Galleri multi-cancer early detection screening,Diagnostic aid for suspected cancer,Precision oncology and MRD/monitoring (RUO methylation platform), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Life Science segment,Clinical Diagnostics segment, |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation analyzers and reagents,Urinalysis, blood gas/electrolyte, and related analyzers, |
| MDXHEALTH | Belgium | Public Company | Confirm mdx (prostate cancer tissue test),ExoD (non-invasive urine prostate cancer test),Genomic Prostate Score collaboration, |
| PERSONALIS, INC. | United States | Public Company | Pharma and biopharma research services (ImmunoID NeXT, exome/transcriptome projects),MRD and clinical liquid biopsy (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling and Dx (NeXT Dx and related tests), |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees, operating as a public company in the healthcare and drug development sector.
CONMED CORPORATION
CONMED Corporation is a U.S.-based public company founded in 1970 with 3,900 employees that manufactures and distributes medical devices and equipment.
HOLOGIC, INC.
Hologic, Inc. is a private U.S. company founded in 1985 with 7,070 employees focused on diagnostic and surgical medical devices.
UNITED IMAGING HEALTHCARE CO., LTD.
United Imaging Healthcare Co., Ltd. is a Chinese public company founded in 2011 with 8,703 employees specializing in medical imaging equipment and solutions.
NATERA, INC.
Natera, Inc. is a U.S. public company founded in 2003 with 6,138 employees providing genetic testing and cell-free DNA analysis services.
GUARDANT HEALTH
Guardant Health is a U.S. public company founded in 2011 with 2,498 employees focused on liquid biopsy and genomic testing for cancer detection.
MYRIAD GENETICS, INC.
Myriad Genetics, Inc. is a U.S. public company founded in 1991 with 2,700 employees specializing in genetic testing and personalized medicine.
ILLUMINA, INC.
Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees that develops and manufactures DNA sequencing and genetic analysis systems.
QIAGEN N.V.
QIAGEN N.V. is a Dutch public company founded in 1984 with 5,500 employees providing molecular diagnostics and life sciences research tools.
EXACT SCIENCES CORPORATION
Exact Sciences Corporation is a U.S. private company founded in 1995 with 7,150 employees specializing in molecular diagnostics and cancer screening.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a U.S. public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and analytical services.
GRAIL, INC.
GRAIL, Inc. is a U.S. public company founded in 2015 with 910 employees focused on early cancer detection through blood-based genomic testing.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a U.S. public company founded in 1952 with 7,450 employees manufacturing clinical diagnostics and life science research products.
SYSMEX CORPORATION
Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees specializing in in vitro diagnostics and hematology analyzers.
MDXHEALTH
MDxHealth is a Belgian public company founded in 2003 with 364 employees providing molecular diagnostics and epigenetic testing services.
PERSONALIS, INC.
Personalis, Inc. is a U.S. public company founded in 2011 with 260 employees offering whole genome sequencing and cancer genomics analysis.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| US | USD 1660.1 Million |
| Canada | USD 281.7 Million |
Country market size visualization
Reasons to Buy this Report
- Market Size & Valuation Data : Access precise market valuations for the US ($1,660.1M) and Canada ($281.7M) with detailed breakdowns enabling accurate financial forecasting and investment decisions for North American operations.
- Growth Projections & CAGR Analysis : Leverage the 11.4% CAGR forecast through 2030 to identify expansion opportunities, plan product launches, and allocate resources strategically across North American markets.
- Competitive Landscape Intelligence : Understand market dynamics specific to North America's advanced healthcare ecosystem, regulatory environment, and reimbursement landscape to benchmark against competitors and identify market gaps.
- Regional Market Segmentation : Gain country-level insights distinguishing the dominant US market from Canada's unique healthcare system, enabling tailored go-to-market strategies and localized business development approaches.
- Strategic Decision Support : Make informed decisions on market entry, partnership development, and portfolio expansion with comprehensive North American data supporting business case development and stakeholder presentations.
Frequently asked questions
What is the current size of the liquid biopsy market in Latin America?
The Latin America liquid biopsy market was valued at $121.6 million in 2025 and is expected to grow to $208.2 million by 2030.
What is the growth rate of the liquid biopsy market in Latin America?
Latin America's liquid biopsy market is growing at a compound annual growth rate (CAGR) of 11.4% from 2025 to 2030.
What factors are driving growth in Latin America's liquid biopsy market?
Latin America's market growth is driven by rising cancer incidence, improving healthcare infrastructure, regulatory support, enhanced reimbursement policies, and increasing adoption of precision medicine diagnostics.
Which countries in Latin America are leading the liquid biopsy market?
Brazil, Mexico, and Argentina are among the largest markets in Latin America for liquid biopsy technologies, supported by advanced healthcare systems and growing diagnostic demand.
What applications are most prevalent in Latin America's liquid biopsy market?
Oncology screening and monitoring represent the largest application segment in Latin America, followed by cardiovascular disease detection and prenatal screening applications.
RESEARCH METHODOLOGY
The study involved estimating activities to determine the current size of the liquid biopsy market. Exhaustive secondary research was done to collect information on the liquid biopsy industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the liquid biopsy market.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| QIAGEN | Sales Manager |
| F. Hoffmann-La Roche Ltd. | Sales Executive |
Market Size Estimation
Liquid biopsy is a non-invasive method for diagnosing and monitoring diseases. Blood or other body fluids are collected to analyze cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or circulating tumor cells (CTCs).
Data Triangulation
After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand & supply sides.
Market Definition
Both top-down and bottom-up approaches were used to estimate and validate the liquid biopsy market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- Primary and secondary research have determined the revenues of leading players operating in the liquid biopsy market.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Stakeholders
- Manufacturers & Distributors of Liquid Biopsy Products
- Hospitals & Diagnostic Centers
- Reference Laboratories
- R&D Companies
- Research Laboratories and Academic Institutes
- Liquid Biopsy Service Providers
- Government Associations
- Venture Capitalists & Investors
Report Objectives
- To define, describe, segment, and forecast the liquid biopsy market, by product & service, circulating biomarker type, technology, application, clinical application, sample type, end user, and region
- To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and challenges)
- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as acquisitions, collaborations, partnerships, agreements, and product launches & approvals in the liquid biopsy market
- To benchmark players within the liquid biopsy market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
Get the Full Liquid Biopsy Market Report
Full forecast, segment splits, and company analysis for all Liquid Biopsy Market.
- US Liquid Biopsy Market
- Canada Liquid Biopsy Market
- Germany Liquid Biopsy Market
- UK Liquid Biopsy Market
- France Liquid Biopsy Market
- Italy Liquid Biopsy Market
- Spain Liquid Biopsy Market
- China Liquid Biopsy Market
- Japan Liquid Biopsy Market
- India Liquid Biopsy Market
- Brazil Liquid Biopsy Market
- Mexico Liquid Biopsy Market
- Rest Of Europe Liquid Biopsy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report